RAGE in inflammation: A new therapeutic target?

Current Opinion in Investigational Drugs

Volumn 7, Issue 11, 2006, Pages 985-991

  Bierhaus, Angelika ^a   Stern, David M ^a   Nawroth, Peter P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Advanced glycation end product; Chronic inflammation; High molecular group box 1 protein; Nuclear facto B; S100 calgranulin; Septicemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; CALGRANULIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; LIGAND; PATTERN RECOGNITION RECEPTOR; PROTEIN S 100;

ANTIINFLAMMATORY ACTIVITY; BETA SHEET; CELL ADHESION; CELL DAMAGE; CELL INFILTRATION; CELL STIMULATION; CELL SURFACE; DIABETES MELLITUS; EXTRAVASATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY DISEASE; LEUKOCYTE; LIGAND BINDING; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TISSUE INJURY;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 33751026851     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yen SF, Schmidt AM: Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology (2005) 15(7):16R-28R.
2. Yan SF, Ramasamy R, Naka Y, Schmidt AM: Glycatlon, inflammation and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 93(12):1159-1169.
3. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R et al: Blockade of receptor for advanced glycation endproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys (2003) 419(1):80-88.
4. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 108(7):949-955.
5. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (2005) 83(11):876-886.
6. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 267(21):14998-15004.
7. Donato R: Intracellular and extracellular roles of S100 proteins. Microsc Res Tech (2003) 60(6):540-551.
8. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P: HMGB1: Guiding immunity from within. Trends Immunol (2005) 26(7):381-387.
9. Stern D, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 54(12):1615-1625.
10. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes (2001) 50(12):2792-2808.
11. Chavakis T, Bierhaus A, Nawroth PP: RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect (2004) 6(13):1219-1225.
12. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, Sayed AA, Andrassy M, Schiekofer S, Schneider JG, Schulz JB et al: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 114:(12)1741-1751.
13. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 162(4):1123-1137.
14. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Grone HJ, Kurschus FC, Schmidt AM, Yan SD et al: Receptor for advanced glycation end products (RAGE) regulates sepals but not the adaptive immune response. J Clin Invest (2004) 113(11):1641-1650.
15. e(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 274(44):31740-31749.
16. e(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest (1999) 104(1):103-113.
17. Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun (2004) 322(4):1111-1122.
18. Yang H, Tracey KJ: High mobility group box 1 (HMGB1). Crit Care Med (2005) 33 (12 Suppl):S472-S474.
19. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD: S100P stimulates cell proliferation and survival via receptor far activated glycation end products (RAGE). J Biol Chem (2004) 279(7):5059-5065.
20. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D: S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res (2006) 312(2):184-197.
21. Muller S, Ronfani L, Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med (2004) 255(3):332-343.
22. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L: Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes (2001) 50(6):1495-1504.
23. Nawroth P, Bierhaus A, Marrero M, Yamamoto H, Stern DM: Atherosclerosis and restenceis: Is there a role for RAGE? Curr Diab Rep (2005) 5(1):11-16.
24. Xiao C, Ghosh S: NF-κB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol (2005) 560:41-45.
25. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med (2003) 198(10):1507-1515.
26. Li J, Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem (1997) 272(26):16498-16506.
27. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H: Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum (2006) 54(1):97-104.
28. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/ calgranulin polypeptides. Cell (1999) 97(7):889-901.
29. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R: Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol (2005) 175(12):8296-8302.
30. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, Bursch LS, Yan SD: Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum (2005) 52(8):2376-2385.
31. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 84(5):489-497.
32. Hudson BI, Harja E, Moser B, Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein? Arterioscler Thromb Vasc Biol (2005) 25(5):879-882.
33. Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF, Schmidt AM: Diabetic vascular disease: It's all the RAGE. Antioxid Redox Signal (2005) 7(11-12):1588-1600.
34. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, LaFaille J, Chess L et al: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 9(3):287-293.
35. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B et al: Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 111(7):959-972.
36. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ, Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA et al: Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2001) 21(6):905-910.
37. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 4(9):1025-1031.
38. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y et al: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 108(22):2827-2835.
39. Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, Stern D, Herold KC: Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 173(2):1399-1405.
40. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM et al: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol (2001) 159(2):513-525.
41. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 405(6784):354-360.
42. Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I: Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol (2005) 64(9):816-830.
43. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS et al: RAGE potentiates Ab-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 23(20):4096-4105.
44. Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE: RAGE and amyloid β interactions: Atomic force microscopy and molecular modeling. Biochim Biophys Acts (2005) 1741(1-2):199-205.
45. Srikrishna G, Huttunen HJ, Johansson L, Weigle B, Yamaguchi Y, Rauvala H, Freeze HH: N-glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem (2002) 80(6):998-1008.
46. Srikrishna G, Turovskaya O, Shaikh R, Newlin R, Foell D, Murch S, Kronenberg M, Freeze HH: Carboxylated glycans mediate colitis through activation of NF-κB. J Immunol (2005) 175(8):5412-5422.
47. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, Tracey KJ et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med (2004) 10(11):1216-1221.
48. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 270(43):25752-25761.
49. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem (2000) 275(51):40096-40105.
50. Yan SF, Ramasamy R, Bucciarelli LG, Wendt T, Lee LK, Hudson BI, Stern DM, Lalla E, S DUY, Rong LL, Naka Y et al: RAGE and its ligands: A lasting memory in diabetic complications? Diab Vasc Dis Res (2004) 1(1):10-20.
51. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation (2003) 108(9):1070-1077.
52. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol (2000) 11(9):1658-1666.
53. e(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci (1999) 40(8):1855-1859.
54. Haslbeck KM, Bierhaus A, Erwin S, Kirchner A, Nawroth P, Schlotzer U, Neundorfer B, Heuss D: Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-κB activation in vasculitic neuropathy. Muscle Nerve (2004) 29(6):853-860.
55. Haslbeck KM, Friess U, Schleicher ED, Bierhaus A, Nawroth PP, Kirchner A, Pauli E, Neundorfer B, Heuss D: The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy. Acta Neuropathol (Berl) (2005) 110(3):247-254.
56. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW: Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: A study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol (2005) 32(1):40-44.
57. Drinda S, Franke S, Ruster M, Petrow P, Pullig O, Stein G, Hein G: Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int (2005) 25(6):411-413.
58. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y: Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: Its possible association with diabetic vascular complications. Diabetes Care (2005) 28(11):2716-2721.
59. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y: Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. Diabetes Care (2006) 29(2):469.
60. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S et al: Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol (2005) 25(12):2587-2593.
61. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther (2005) 7(4):R817-R824.
62. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D: Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol (2005) 62(11):1734-1736.
63. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG et al: RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun (2002) 3(3):123-135.
64. Prevost G, Fajardy I, Besmond C, Balkau B, Tichet J, Fontaine P, Danze PM, Marre M: Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab (2005) 31(1):35-39.
65. Rudofsky G Jr, Isermann B, Schilling T, Schiekofer S, Andrassy M, Schneider JG, Morcos M, Humpert PM, Sayed AA, Wile S, Renn W et al: A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes (2004) 112(3):135-141.
66. Chang C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol (2005) 18(10):1385-1398.
67. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol (2005) 25(5):1032-1037.
68. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G et al: Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol (2005) 16(8):2363-2372.
69. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, Egido J: Renal and vascular hypertension-induced inflammation: Role of angiotensin II. Curr Opin Nephrol Hypertens (2006) 15:159-166.
70. Humpert PM, Kopf S, Djuric Z, Wendt T, Morcos M, Nawroth PP, Bierhaus A: Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diab Care (2006) 29(5):1111-1113.
71. Morena MD, Guo D, Balakrishnan VS, Brady JA, Winchester JF, Jaber BL: Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int (2003) 63(3):1150-1154.
72. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B, Stenvinkel P: Enhanced RAGE-mediated NF-κB stimulation in inflamed hemodialysls patients. Atherosclerosis (2005) 180(2):333-340.
73. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant (2002) 17(16):1045-1049.
74. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant (2001) 16(5):999-1008.
75. Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm A: Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med (2004) 170(5):516-519.
76. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillaussesu PJ, Cao R, Hori O, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest (1996) 97(1):238-243.